These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28190597)

  • 21. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
    Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 23. Patients and caregivers costs for colonoscopy-based colorectal cancer screening: Experience of low-income individuals undergoing free colonoscopies.
    Hoover S; Subramanian S; Tangka FKL; Cole-Beebe M; Sun A; Kramer CL; Pacillio G
    Eval Program Plann; 2017 Jun; 62():81-86. PubMed ID: 28153341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
    Lee KS; Park EC
    Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
    Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
    Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
    Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outpatient colonoscopy complications in the CDC's Colorectal Cancer Screening Demonstration Program: a prospective analysis.
    Castro G; Azrak MF; Seeff LC; Royalty J
    Cancer; 2013 Aug; 119 Suppl 15():2849-54. PubMed ID: 23868479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of planning and implementing the CDC's Colorectal Cancer Screening Demonstration Program.
    Subramanian S; Tangka FK; Hoover S; Beebe MC; DeGroff A; Royalty J; Seeff LC
    Cancer; 2013 Aug; 119 Suppl 15(Suppl 15):2855-62. PubMed ID: 23868480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.
    Aronsson M; Carlsson P; Levin LÅ; Hager J; Hultcrantz R
    Br J Surg; 2017 Jul; 104(8):1078-1086. PubMed ID: 28561259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expenditures on Screening Promotion Activities in CDC's Colorectal Cancer Control Program, 2009-2014.
    Tangka FKL; Subramanian S; Hoover S; Cole-Beebe M; DeGroff A; Joseph D; Chattopadhyay S
    Prev Chronic Dis; 2019 Jun; 16():E72. PubMed ID: 31172915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs. colonoscopy.
    Wong MC; Ching JY; Chan VC; Sung JJ
    Sci Rep; 2015 Sep; 5():13568. PubMed ID: 26338314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals.
    Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH
    Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal occult blood testing when colonoscopy capacity is limited.
    Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
    J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated telephone calls to enhance colorectal cancer screening: economic analysis.
    Smith DH; Feldstein AC; Perrin N; Rosales AG; Mosen DM; Liles EG; Schneider JL; Lafata JE; Meyers RE; Glasgow RE
    Am J Manag Care; 2012 Nov; 18(11):691-9. PubMed ID: 23198712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results and cost-effectiveness of colorectal cancer screening program among urban residents in Zhejiang province, 2013-2018].
    Wang L; Li HZ; Zhu C; Wang YQ; Zhou HJ; Sun XH; Zhang MZ; Jin L; Du LB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2080-2086. PubMed ID: 33378820
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies.
    Barichello S; Deng L; Ismond KP; Loomes DE; Kirwin EM; Wang H; Chang D; Svenson LW; Thanh NX
    Int J Colorectal Dis; 2019 Nov; 34(11):1953-1962. PubMed ID: 31673772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.